Odyssey VC is a venture capital firm that focuses on investing in innovative startups and supporting entrepreneurs in various stages of growth. The firm leverages its expertise and network to help companies scale and succeed in the market.

Odyssey VC

At Odyssey, we are creating next generation precision medicines for patients with cancer and inflammatory diseases with class-leading speed, efficiency and rigor through our highly integrated drug hunting engine.

In response to recent recruitment fraud, visit our Careers page to verify all job opportunities and read our guidance on this topic: https://odysseytx.com/careers/

OrbiMed

Creacion Ventures

Foresite Capital

Logos Capital

Colt Ventures

Woodline Partners

SR One

HBM Healthcare Investments AG

Fidelity Management and Research Company

Walleye Capital

T. Rowe Price

General Catalyst

GreatPoint Ventures

HBM Partners

Ascenta Capital

BlackMars Capital

The Healthcare Innovation Investment

Global BioAccess Fund

Odyssey Therapeutics

“Odyssey’s accomplished team of scientists and executives with numerous prior successes in discovery, development and commercialization has made tremendous progress in only two years. Dr. Glick has successfully created a sustainable and capital-efficient model that primes Odyssey to be a hub for immunology and oncology therapeutic innovation, and I look forward to working with him, the board and leaders on the management team in the years ahead.” Dr. Lorence Kim, co-founder and managing partner of Ascenta Capital 

Today, we announce the closing of a $101 million Series C financing round led by Ascenta Capital with participation from new and existing investors, and welcome Dr. Lorence Kim to our board of directors. This funding will support the advancement of multiple programs into clinical studies and the continuation of investment in discovery to build a sustainable model for therapeutic innovation.  

Read the full press release: https://lnkd.in/gHVi7K2q 

#Biotech #DrugDiscovery #PrecisionMedicine #Therapeutics 

We have entered a strategic research collaboration with Johnson & Johnson Innovative Medicine to jointly discover and optimize small molecule medicines. Together, we will combine our expertise in #ArtificialIntelligence (AI), #MachineLearning (ML), computational chemistry and drug discovery to unlock difficult-to-drug targets.

“This collaboration between our chemists, biologists, and data scientists will help accelerate our joint drug discovery efforts through optimization of our tools, data sharing, and model development to discover and develop transformational medicines for patients in need,” said Gary D. Glick, founder and CEO of Odyssey Therapeutics.

Learn more in our press release: https://lnkd.in/e-DDCMeF 

#DrugDiscovery #DataScience

“As we take extraordinary leaps to improve patient outcomes, we continue to recruit the best and brightest to join our team,” said Gary D. Glick, founder and CEO of Odyssey Therapeutics. “Ms. Clauss and Dr. Butler have proven track records of successfully leading teams to achieve strategic business and research goals.” 

Today, we welcome Julie Clauss as chief operating officer and Christopher Butler as senior vice president, head of Chemistry. Leveraging their incredible expertise, we will continue to push new frontiers in drug discovery and development for patients living with serious diseases. Welcome to #TeamOdyssey Julie and Christopher! 

Full press release: https://lnkd.in/gX3_9Bfq 

#Leadership #Biotech #DrugDiscovery #PrecisionMedicine #Therapeutics 

Meet Melissa Christine Holt, a Senior Research Scientist at #TeamOdyssey. Melissa joined two years ago to help build a therapeutics pipeline focused on patient benefit. Her role involves coupling her experience and knowledge of drug design with the labor of chemical synthesis to find small molecules capable of being medicines. Melissa believes that Odyssey's talented team has created a highly diversified pipeline, positioning us for success. 

Aside from her work, Melissa enjoys outdoor activities such as kayaking, skiing, hiking, and camping. We're thrilled to have her on our team and look forward to seeing what she accomplishes next! #EmployeeSpotlight 

Congratulations to IFM Therapeutics and Gary D. Glick, Odyssey Founder and CEO, and IFM Founder, former CEO, and current Chairman, who today announced the sale of its subsidiary, IFM Due, and accompanying portfolio of STING antagonist programs to Novartis. This sale represents a landmark third acquisition of an IFM program since the company’s founding in 2015 and is a testament to the hard work and dedication of IFM CEO H. Martin Seidel and team. Congrats to all who played a role in this pivotal milestone. 

Acquisition info here: https://lnkd.in/g-f47YjH 

COM:ODYSSEYTX

Odyssey VC

Financials Not Available